Adjuvant chemotherapy for locally advanced cervical cancer

We thank Sezin Yuce Sari and colleagues for their interest and comments regarding our Article. 1 Mileshkin LR Moore KN Barnes EH et al. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023; 24: 468-482 Summary Full Text Full Text PDF PubMed Scopus (4) Google Scholar We too were disappointed that adjuvant chemotherapy after chemoradiotherapy for locally advanced cervical cancer did not improve overall survival in OUTBACK. We disagree that these findings are explained by patient selection, outdated radiotherapy, or non-adherence to adjuvant chemotherapy. Adjuvant chemotherapy for locally advanced cervical cancerWe read the Article by Linda R Mileshkin and colleagues1 with great interest. Although awaited eagerly, the absence of improvement in progression-free and overall survival with the addition of adjuvant chemotherapy in patients with locally advanced cervical cancer was very disappointing. Nevertheless, having read the details of the study, we still think selected patients might benefit from adjuvant chemotherapy. Full-Text PDF Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trialAdjuvant carboplatin and paclitaxel chemotherapy given after standard cisplatin-based chemoradiotherapy for unselected locally advanced cervical cancer increased short-term toxicity and did not improve overall survival; therefore, it should not be given in this setting. Full-Text PDF